İfosfamide uygulanan Wistar Albino sıçanlarda sitogenetik incelemeler
Başlık çevirisi mevcut değil.
- Tez No: 40787
- Danışmanlar: PROF.DR. ASIM CENANİ
- Tez Türü: Yüksek Lisans
- Konular: Tıbbi Biyoloji, Medical Biology
- Anahtar Kelimeler: DNA, Hücre döngüsü, Kromozomlar, Mutasyon, Sitogenetik, Sıçanlar, İfosfamide, İlaç tedavisi, DNA, Cell cycle, Chromosomes, Mutation, Cytogenetics, Rats, Ifosfamide, Drug therapy
- Yıl: 1994
- Dil: Türkçe
- Üniversite: İstanbul Üniversitesi
- Enstitü: Sağlık Bilimleri Enstitüsü
- Ana Bilim Dalı: Genetik Ana Bilim Dalı
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: Belirtilmemiş.
Özet
91 SUMMARY Chemical mutagens intrupt DNA replication and cell division and may cause chromosome aberrations, both structural and numerical. A major group of chemical mutagens are drugs. These include alkylating agents, nucleic acid analogues, cytotoxics and antibiotics. In this study the mutagenic effect of Ifosfamide has been tested. Ifosfamide is a cytotoxic alkylating antineoplastic agent belonging to oxazaphosphorine family chromosome analysis has been performed on direct bone marrow preparations of 45 Wistar Albino rats (IS controls and 30 subjects) after in vivo application of 25 mg/kg, 100 mg/kg and 400 mg/kg of Ifosfamide. Mitotic index, chromosome structure and number changes has been compared in doses groups. Mitotic index has decreased significantly in the 100 mg/kg and 400 mg/kg groups. A significant increase in chromosome and chromatid type gaps and breaks, and numerical aberrations has been noted in all dosis groups. Increase in aberrations was proportional to the increase in dosis. As a result Ifosfamide has been found to have a highly mutagenic and especially clastogenic effect, supporting the previous findings.
Özet (Çeviri)
91 SUMMARY Chemical mutagens intrupt DNA replication and cell division and may cause chromosome aberrations, both structural and numerical. A major group of chemical mutagens are drugs. These include alkylating agents, nucleic acid analogues, cytotoxics and antibiotics. In this study the mutagenic effect of Ifosfamide has been tested. Ifosfamide is a cytotoxic alkylating antineoplastic agent belonging to oxazaphosphorine family chromosome analysis has been performed on direct bone marrow preparations of 45 Wistar Albino rats (IS controls and 30 subjects) after in vivo application of 25 mg/kg, 100 mg/kg and 400 mg/kg of Ifosfamide. Mitotic index, chromosome structure and number changes has been compared in doses groups. Mitotic index has decreased significantly in the 100 mg/kg and 400 mg/kg groups. A significant increase in chromosome and chromatid type gaps and breaks, and numerical aberrations has been noted in all dosis groups. Increase in aberrations was proportional to the increase in dosis. As a result Ifosfamide has been found to have a highly mutagenic and especially clastogenic effect, supporting the previous findings.
Benzer Tezler
- Küçük hücreli dışı inoperabil akciğer kanserlerinde mitomycin, ifosfamide, cisplatin (MIC) ve vinorelbine, cisplatin (VRB-P) kombinasyonlarının karşılaştırılması
Başlık çevirisi yok
ADVİYE ÖZER
Tıpta Uzmanlık
Türkçe
1997
Göğüs HastalıklarıOndokuz Mayıs ÜniversitesiGöğüs Hastalıkları Ana Bilim Dalı
- Nöroblastomda tedavi ile sağkalım ilişkisi ve sağkalıma etki eden faktörler
Neuroblastoma: The Influence of treatment on survival and the prognostic factors
SEZA OKAN
Tıpta Uzmanlık
Türkçe
1995
Çocuk Sağlığı ve Hastalıklarıİstanbul ÜniversitesiÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
PROF. DR. LEYLA AĞAOĞLU
- Germ hücreli testis kanserlerinde 78 aylık izlem ve kemoterapi sonuçları
The results of 78-month follow-up and chemotherapy in patients with testicular germ cell cancer
AHMET BEKİR ÖZTÜRK
Tıpta Uzmanlık
Türkçe
1994
Endokrinoloji ve Metabolizma HastalıklarıGataİç Hastalıkları Bilim Dalı
PROF.DR. MUSTAFA KUTLU
- İleri evre küçük hücre dışı akciğer kanserinde üç farklı kombine kemoterapi şemasının birbirleri ile ve radyoterapi verilen grupla tedavi cevaplarının karşılaştırılması
A Comparison of three cisplatin-based chemotherapy regimens and radiotherapy in stage 3-B and stage 4 nonsmall cell lung carcinoma patients
AYŞE AYAZ